Sichenzia Ross Friedman Ference LLP Advises Citius Pharmaceuticals, LLC on a Reverse Merger and $2.04 Million Pipe Financing
September 18, 2014 (GLOBE NEWSWIRE) – New York – based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Citius Pharmaceuticals, LLC (OTCQB: CTXR) – a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets- in connection with a Share Exchange and Reorganization Agreement between Citius Pharmaceuticals, LLC, Citius Pharmaceuticals, Inc. (formerly known as Trail One. Inc.) and the beneficial holders of the membership interests of Citius.
Pursuant to the “Exchange Agreement”, Citius Pharmaceuticals, Inc. issued common stock to the holders of the membership interests of Citius representing approximately 72.0% of the outstanding shares of common stock.
In connection with the “Exchange Agreement”, Sichenzia Ross advised Citius on a private offering whereby Citius sold 3,4000,067 Units for a purchase price of $0.60 per Unit for a total value of $2.04 million. Each Unit sold consisted of one share of common stock and a five-year warrant. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia and Arthur S. Marcus.
Media Contact:
pr@srf.law
Visit SRFC's LinkedIn page
- Sichenzia Ross Ference Carmel LLP Represents New Era Helium in De-SPAC Transaction and Nasdaq Listing - December 9, 2024
- Sichenzia Ross Ference Carmel LLP represents Madison Global Partners, LLC in an Unsecured Senior Convertible Note and Warrant Offering up to $1 Million - December 6, 2024
- Sichenzia Ross Ference Carmel LLP Represents D. Boral Capital in $1.7 Million Registered Direct Offering of SRM Entertainment - December 5, 2024
